Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Imunon Inc IMNN

Healthcare Biotechnology
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment... see more

Recent & Breaking News (NDAQ:IMNN)

CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

GlobeNewswire April 6, 2022

Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial

GlobeNewswire April 6, 2022

Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021

GlobeNewswire April 1, 2022

Celsion Corporation Reports 2021 Financial Results and Provides Business Update

GlobeNewswire March 31, 2022

Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022

GlobeNewswire March 24, 2022

Celsion Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses

GlobeNewswire February 28, 2022

Celsion Corporation Announces Stock Consolidation

GlobeNewswire February 28, 2022

Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

GlobeNewswire February 17, 2022

Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate

GlobeNewswire January 31, 2022

Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock

GlobeNewswire January 13, 2022

Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock

GlobeNewswire January 10, 2022

Celsion Corporation Invited to Present Poster at Cytokine-Based Cancer Immunotherapies Summit

GlobeNewswire November 29, 2021

Celsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire November 15, 2021

Celsion Corporation to Hold Third Quarter 2021 Financial Results and Business Update Conference Call on Monday, November 15, 2021

GlobeNewswire November 9, 2021

Celsion Provides Update on its Application to Sell $1.5 Million of New Jersey Net Operating Losses

GlobeNewswire November 8, 2021

Celsion Corporation's GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies Summit

GlobeNewswire November 8, 2021

Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress

GlobeNewswire October 15, 2021

Celsion Corporation Announces Oral Presentation at International Vaccines Congress

GlobeNewswire October 12, 2021

Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® Drug Development in Advanced Drug Delivery Reviews

GlobeNewswire October 11, 2021

Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities

GlobeNewswire October 5, 2021